

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, October 23, 2019

In accordance with Article 17 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and Article 227 of the consolidated text of the Securities Market Act, the following **RELEVANT EVENT** is hereby reported:

The Board of Directors of Pharma Mar, S.A. (the "Company"), at its meeting held today, has agreed to appoint Mr. Valentín de Torres-Solanot del Pino, independent director, as Chairman of the Audit Committee, of which he was already a member, for the same period of validity of his position as Director of the Company, replacing Mr. Carlos Solchaga Catalán, whose four-year term is due to expire on November 2nd, 2019. Mr. Carlos Solchaga Catalán continues as a member of the said Commission.

Consequently, after the aforementioned appointment, the current composition of the Audit Committee is as follows:

Chairman: Mr. Valentín de Torres-Solanot del Pino
Member: Ms. Ana Palacio Vallelersundi
Member: Mr. José Félix Pérez-Orive Carceller
Member: ROSP CORUNNA PARTICIPACIONES EMPRESARIALES, S.L.
(represented by D. José Leyte Verdejo)
Member: Mr. Carlos Solchaga Catalán
Non-member Secretary: Mr. Juan Gómez Pulido